Monthly Archives: April 2014

Clostridium difficile strain RT244 - Australia researchers

Researchers from Monash University in Australia have found that the RT244 Clostridium difficile strain, which was associated with severe disease and a high mortality rate, has significant pathogenic potential.

While there have been three separate known introductions of RT 027 into Australia in 2008 and two in 2010, the strain has not established here, possibly because of Australia’s conservative policies regarding fluoroquinolones. Nevertheless, there has been a significant increase in the rate of CDI in Australia over the past 3–4 years. Surveillance of hospital-identified (HI) CDI was mandated for public healthcare facilities in Western Australia in January 2010. The quarterly aggregate rate climbed from 1.47 per 10,000 bed days in the first quarter of 2010 to 2.64 per 10,000 bed days in the fourth quarter of 2010 and 4.59 per 10,000 bed days a year later, falling slightly to 4.27 per 10,000 bed days in the fourth quarter of 2012. Rates were approximately 1–3 times higher for tertiary hospitals alone3,4. In a laboratory-based, retrospective review of all cases of CDI identified in four acute care public hospitals in Tasmania between July 2006 and June 2010 inclusive, the annual rate increased from 2.5 per 10,000 patient-care days in 2006–07 to 4.2 per 10,000 patient-care days in 2009–105. The first report from Victoria following the commencement of targeted surveillance for CDI in 2010 was for the period October 2010 to March 2011 inclusive6. They reported a monthly increase in the number of HI-CDI cases, falling only in December 2010, and an overall rate of 2.2 per 10,000 occupied bed days. - See more at: http://microbiology.publish.csiro.au/?paper=MA14008#sthash.RVdbbLhF.dpuf
While there have been three separate known introductions of RT 027 into Australia in 2008 and two in 2010, the strain has not established here, possibly because of Australia’s conservative policies regarding fluoroquinolones. Nevertheless, there has been a significant increase in the rate of CDI in Australia over the past 3–4 years. Surveillance of hospital-identified (HI) CDI was mandated for public healthcare facilities in Western Australia in January 2010. The quarterly aggregate rate climbed from 1.47 per 10,000 bed days in the first quarter of 2010 to 2.64 per 10,000 bed days in the fourth quarter of 2010 and 4.59 per 10,000 bed days a year later, falling slightly to 4.27 per 10,000 bed days in the fourth quarter of 2012. Rates were approximately 1–3 times higher for tertiary hospitals alone3,4. In a laboratory-based, retrospective review of all cases of CDI identified in four acute care public hospitals in Tasmania between July 2006 and June 2010 inclusive, the annual rate increased from 2.5 per 10,000 patient-care days in 2006–07 to 4.2 per 10,000 patient-care days in 2009–105. The first report from Victoria following the commencement of targeted surveillance for CDI in 2010 was for the period October 2010 to March 2011 inclusive6. They reported a monthly increase in the number of HI-CDI cases, falling only in December 2010, and an overall rate of 2.2 per 10,000 occupied bed days. - See more at: http://microbiology.publish.csiro.au/?paper=MA14008#sthash.RVdbbLhF.dpuf

They conducted a retrospective cohort study that included 12 patients with the RT244 strain and 24 matched patients with a non-RT244/non-RT027 strain. They performed whole-genome sequencing on the strains to understand how the RT244 strain was related to other strains. There was no difference in age or comorbidities between the two groups and most patients had antibiotic exposure.

* While there have been three separate known introductions of RT 027 into Australia in 2008 and two in 2010, the strain has not established here, possibly because of Australia’s conservative policies regarding fluoroquinolones. Nevertheless, there has been a significant increase in the rate of CDI in Australia over the past 3–4 years. Surveillance of hospital-identified (HI) CDI was mandated for public healthcare facilities in Western Australia in January 2010. The quarterly aggregate rate climbed from 1.47 per 10,000 bed days in the first quarter of 2010 to 2.64 per 10,000 bed days in the fourth quarter of 2010 and 4.59 per 10,000 bed days a year later, falling slightly to 4.27 per 10,000 bed days in the fourth quarter of 2012. Rates were approximately 1–3 times higher for tertiary hospitals alone3,4. In a laboratory-based, retrospective review of all cases of CDI identified in four acute care public hospitals in Tasmania between July 2006 and June 2010 inclusive, the annual rate increased from 2.5 per 10,000 patient-care days in 2006–07 to 4.2 per 10,000 patient-care days in 2009–105. The first report from Victoria following the commencement of targeted surveillance for CDI in 2010 was for the period October 2010 to March 2011 inclusive6. They reported a monthly increase in the number of HI-CDI cases, falling only in December 2010, and an overall rate of 2.2 per 10,000 occupied bed days.

Another potential explanation for the increase in CDI rates is the emergence of new strains. RT 244 was first identified in Australia in 2011 and preliminary data suggested it was associated with more severe disease. This was recently supported by De Almeida et al.12 who, after identifying a new strain in New Zealand as RT 244, performed a case-control study of cases with CDI due to this RT. Cases had more severe disease (OR 9.33; P = 0.015) and were more likely to have community-associated infections (prevalence ratio 3.33; P = 0.078) when compared with controls who were infected with other C. difficile strains. Like RT 027, RT 244 produces more toxins A and B as a result of a single base pair deletion in tcdC (a gene involved in regulation of toxin A and B production), as well as binary toxin. RT 244 is therefore identified as a putative RT 027 with the Cepheid Xpert® C. difficile/Epi system. Other emerging RTs in Australia include RT 251 (A+B+CDT+), which also appears to be closely related to RT 027, and RT 033 (ABCDT+), RT 126 (A+B+CDT+) and RT 127 (A+B+CDT+), which are closely related to RT 078 (A+B+CDT+), a RT originally only isolated from animals, particularly livestock, in the Northern hemisphere and also associated with more severe disease - See more at: http://microbiology.publish.csiro.au/?paper=MA14008#sthash.RVdbbLhF.dpuf
Another potential explanation for the increase in CDI rates is the emergence of new strains. RT 244 was first identified in Australia in 2011 and preliminary data suggested it was associated with more severe disease. This was recently supported by De Almeida et al.12 who, after identifying a new strain in New Zealand as RT 244, performed a case-control study of cases with CDI due to this RT. Cases had more severe disease (OR 9.33; P = 0.015) and were more likely to have community-associated infections (prevalence ratio 3.33; P = 0.078) when compared with controls who were infected with other C. difficile strains. Like RT 027, RT 244 produces more toxins A and B as a result of a single base pair deletion in tcdC (a gene involved in regulation of toxin A and B production), as well as binary toxin. RT 244 is therefore identified as a putative RT 027 with the Cepheid Xpert® C. difficile/Epi system. Other emerging RTs in Australia include RT 251 (A+B+CDT+), which also appears to be closely related to RT 027, and RT 033 (ABCDT+), RT 126 (A+B+CDT+) and RT 127 (A+B+CDT+), which are closely related to RT 078 (A+B+CDT+), a RT originally only isolated from animals, particularly livestock, in the Northern hemisphere and also associated with more severe disease - See more at: http://microbiology.publish.csiro.au/?paper=MA14008#sthash.RVdbbLhF.dpuf
Another potential explanation for the increase in CDI rates is the emergence of new strains. RT 244 was first identified in Australia in 2011 and preliminary data suggested it was associated with more severe disease. This was recently supported by De Almeida et al.12 who, after identifying a new strain in New Zealand as RT 244, performed a case-control study of cases with CDI due to this RT. Cases had more severe disease (OR 9.33; P = 0.015) and were more likely to have community-associated infections (prevalence ratio 3.33; P = 0.078) when compared with controls who were infected with other C. difficile strains. Like RT 027, RT 244 produces more toxins A and B as a result of a single base pair deletion in tcdC (a gene involved in regulation of toxin A and B production), as well as binary toxin. RT 244 is therefore identified as a putative RT 027 with the Cepheid Xpert® C. difficile/Epi system. Other emerging RTs in Australia include RT 251 (A+B+CDT+), which also appears to be closely related to RT 027, and RT 033 (ABCDT+), RT 126 (A+B+CDT+) and RT 127 (A+B+CDT+), which are closely related to RT 078 (A+B+CDT+), a RT originally only isolated from animals, particularly livestock, in the Northern hemisphere and also associated with more severe disease - See more at: http://microbiology.publish.csiro.au/?paper=MA14008#sthash.RVdbbLhF.dpuf
Another potential explanation for the increase in CDI rates is the emergence of new strains. RT 244 was first identified in Australia in 2011 and preliminary data suggested it was associated with more severe disease. This was recently supported by De Almeida et al.12 who, after identifying a new strain in New Zealand as RT 244, performed a case-control study of cases with CDI due to this RT. Cases had more severe disease (OR 9.33; P = 0.015) and were more likely to have community-associated infections (prevalence ratio 3.33; P = 0.078) when compared with controls who were infected with other C. difficile strains. Like RT 027, RT 244 produces more toxins A and B as a result of a single base pair deletion in tcdC (a gene involved in regulation of toxin A and B production), as well as binary toxin. RT 244 is therefore identified as a putative RT 027 with the Cepheid Xpert® C. difficile/Epi system. Other emerging RTs in Australia include RT 251 (A+B+CDT+), which also appears to be closely related to RT 027, and RT 033 (ABCDT+), RT 126 (A+B+CDT+) and RT 127 (A+B+CDT+), which are closely related to RT 078 (A+B+CDT+), a RT originally only isolated from animals, particularly livestock, in the Northern hemisphere and also associated with more severe disease - See more at: http://microbiology.publish.csiro.au/?paper=MA14008#sthash.RVdbbLhF.dpuf

- See more at: http://microbiology.publish.csiro.au/?paper=MA14008#sthash.RVdbbLhF.dpuf

They found that the patients with the RT244 strain had more severe disease, renal impairment and hypoalbuminemia compared with non-RT244 patients. These patients also were more likely to die: They had a 30-day mortality of 42% and four of the five deaths were attributed to CDI. There were no deaths among patients with non-RT244 strains. Patients with the RT244 strain were 13 times more likely to die compared with those with non-RT244 strains.

In a phylogenomic analysis, the researchers found that the RT244 strain is in the same genetic clade as the strain RT027 (clade 2). In further analyses, the researchers found that the RT244 strain produced a variant toxin B, which may be the contributing factor to the strain’s virulence.

“The overall clinical significance of RT244 cannot be clearly determined at present,” the researchers wrote in Clinical Infectious Diseases. “At our laboratory, C. difficile RT244 has spontaneously declined and the epidemiological data available to us provided no clear evidence for the source of the strain, how it disseminated in our community or why its incidence has declined. Further studies are required to answer these questions, and to better understand the virulence of the strain, and its potential to become endemic and to cause further outbreaks.”

Lim S. Clin Infect Dis. 2014;doi:10.1093/cid/ciu203.

April 2014

To view article in its entirety please click on the following link:

http://www.healio.com/infectious-disease/gastrointestinal-infections/news/online/%7Baded8e63-618e-4300-a1ad-f8402cbfd011%7D/newly-identified-c-difficile-strain-highly-virulent?utm_content=buffer1eab0&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

C. difficile infection; Maintaining Nutrition

matzo-ball-soup

 

 

 

As we know those combating a C-Diff Infection deal with the major symptom; diarrhea. This can cause a person to lose large amounts of water, alter electrolytes, and loose minerals. However, certain foods can help one to overcome the symptoms of diarrhea. It is important to drink clear liquids such as juices, decaffeinated tea, or sports drinks, gelatin, frozen ices, and water. Bland foods are also appropriate such as applesauce, bananas, canned soft fruits, crackers, eggs, mashed potatoes, pretzels, smooth nut butters, toast, white rice and especially soups.

* Please Note: If an individual is unable to maintain adequate hydration and nutrition, contact the Physician and seek medical attention as soon as possible. Dehydration can be life threatening *

Soups provide fluid, sodium, calories and vitamins. One soup that provides fluid replacement, protein, maintains nutrition, and is relatively easy to prepare is a simple matzoh ball soup.

Recipe: Matzoh Ball soup

2 quarts of salted water
3 eggs,
¼ cup of oil
Large dash each salt and pepper
1 cup of matzoh meal(approx)

Bring water to a boil. While you are waiting for water to heat combine eggs, oil, salt and pepper. Then mix in matzoh meal, a little at a time, until the mixture is thickened but still sticky. Matzoh meal absorbs lots of water, so wait 10 minutes or so to see if you need more. Aim for your batter to feel like modeling clay.

Wet your hands and roll batter into balls; for large balls, roll them into the size of a small egg. For smaller balls, aim for walnut-sized. Drop balls into the boiling water, then reduce heat and simmer for at least 30 minutes.

Makes approx 12 small matzoh balls.

 

April 2014: K. Factor, R.D., MS - Chairperson of Nutrition Wellness

SIBO updates from Drs. Siebecker and Sandberg-Lewis

SIBO test interpretation

New article from Drs. Siebecker and Sandberg-Lewis

Confused about how to interpret the results of breath tests? Dr. Sandberg-Lewis and I recently published an article with pictures of many test examples and scenarios of interpretation. See it here in the Jan NDNR edition online.

Note: The article was written before Dr. Pimentel presented his new methane level of 3ppm as positive at the SIBO Symposium (see below)

SIBO Symposium highlights

New info from the 2014 SIBO Symposium

For anyone who missed it — the 2014 SIBO Symposium webinar recordings are now available for purchase, either as individual classes or together as the whole. It was a fantastic event packed with info. Between webinar participation and in person, close to 600 people attended the symposium. We’re planning the next Symposium for 2015 (date to be determined).


Dr. Sandberg-Lewis and myself lecturing.


Dr. Pimentel lecturing in front a sold-out audience.

Here are some points of interest from the symposium (from the notes of Dr. Nirala Jacobi and myself):

  • SIBO is caused by something (obstruction, decreased motility/ICC damage, non-draining pockets…); don’t stop at SIBO treatment — find the cause
  • Cdt B toxin from bacterial food poisoning, triggers autoimmunity to vinculin on ICC nerve cells, slowing motility — the cause of a majority of SIBO cases is autoimmune nerve damage
  • Too much protein for dinner during the prep diet (a big steak) is contraindicated as it slows transit
  • Hard-aged cheese, which is lactose free, is OK on the prep diet
  • Methane of 3ppm at any place during the lactulose test is positive
  • Flat lining of both hydrogen and methane on the test is indicative of hydrogen sulfide gas
  • Rifaximin is bile-soluble but not water-soluble — it can penetrate the small intestine biofilm and then loses effect in the large intestine due to crystallization
  • Neem potentiates other herbals
  • .5mg Resolor (prucalopride) is a good starting dose for SIBO prevention in most — previous common starting dose was 1mg
  • Leaky gut is only present in about half of SIBO patients and heals within one month of eradication — without supplements
  • Leave 4-5 hours between meals on any SIBO Diet to allow MMCs — no snacking
  • Clover honey has a 50:50 glucose to fructose ratio- according to breath testing, it absorbs normally in fructose malabsorbers

Questions? -See the webinar recording

New Youtube video

Great 6 minute video Interview with Dr. Pimentel on IBS and SIBO

 

New podcast interview

With Dr. Siebecker — I really enjoyed this one because hosts Darren and Diane asked me some different questions than I usually get and were wonderful to chat with: Wellness Warrior Radio

Updated handout

SIBO Symptomatic Relief Suggestions” has been updated to include a homemade electrolyte recipe

Update to website

Discussion of semi-elemental formula was removed since clinically these have not proven effective. (not to be confused with elemental formulas which have an excellent success rate)

New FODMAP book

Diet inventors Drs. Shepard and Gibson came out with an official book last year — The Complete Low-Fodmap Diet. It contains both explanations and recipes.

Hot Off the Press — 2014 PubMed Articles on SIBO:

2014 FODMAPs Articles

Warmly,

Dr. Allison Siebecker, ND, LAc
siboinfo.com

Our mailing address is:

Dr Allison Siebecker

Portland Or

Portland, Or 97086

Add us to your address book

What you can do while experiencing symptoms of diarrhea

WaterFruit

What can you do while experiencing symptoms of diarrhea?
Liquids
Drink plenty of liquids between meals to avoid dehydration. Water, broth, gelatin, ices, and sports drinks are all good choices.
Room temperature
Some people tolerate liquids at room temperature better than those served hot or cold.
Sugar-free foods
Avoid sugar-free foods when you have diarrhea. The sugar alcohols used to sweeten these foods, such as sorbitol and xylitol, can worsen diarrhea.
Dairy products
Do not consume dairy products when symptoms are most severe. Add low-fat or fat-free milk back into your diet slowly.
Small meals
Have small meals and snacks, rather than big meals.
Bland foods
It is recommended that you choose bland foods when you have diarrhea.
Good choices include:
  • Applesauce
  • Bananas
  • Canned soft fruits
  • Cooked hot cereals
  • Crackers
  • Eggs
  • Mashed potatoes
  • Pretzels
  • Smooth nut butters
  • Soup
  • Toast
  • White rice
Foods to avoid
Do not choose foods that are greasy, fried, or fatty. Do not add butter, oil, or other fats to your foods. Certain foods tend to cause discomfort for many patients, including:
  • Beets
  • Broccoli
  • Brussels sprouts
  • Cabbage
  • Carbonated beverages
  • Cauliflower
  • Corn
  • Dried beans
  • Dried fruit
  • Fried or fatty meats
  • Greens
  • High-fiber breads
  • High-fiber cereals
  • Nuts
  • Onions
  • Raw fruits (except bananas and melon)
  • Raw vegetables
  • Whole grains
  • Whole milk
Grains
Choose grains that contain less than 2 grams of fiber/serving.
* CLEAR LIQUID DIETS are only to be followed for three (3) days. If adequate
nutrition or hydration can not be maintained, please contact the Physician and health
care professionals promptly and seek medical attention.
Meats, chicken, and fish
Select lean meats, chicken, and fish.
Yogurt
Patients with diarrhea caused by antibiotics may benefit form adding yogurt to their diet.
When should the physician be notified?
Call your doctor if you:
  • Have mucus, blood, or pus in your stools
  • Have diarrhea lasting longer than 2 to 3 days
  • Have not urinated in 12 hours
  • Have severe pain or abdominal cramping
  • Are vomiting and experiencing diarrhea at the same time
  • Have a chronic illness, such as diabetes
  • Have a high fever (more than 101º F)
  • Are pregnant
  • Experience rapid breathing, fever, or dizziness
  • If you have traveled to a foreign country, or have taken an antibiotic recently or in the past two/three months, or have developed diarrhea upon your return from any visit out of your immediate area.
Remember to:
  • Eat and drink whatever you think will work best for you
  • Frequent hand-washing breaks and for a minimum of twenty (20) seconds, before exiting a restroom, before/after eating, before/after entering a patients room, before/after wearing gloves during patient care, after changing diapers, after grooming and handling pets and Wash hands often.
  • Eat and drink small portions, gradually increasing your diet as tolerated
References and recommended readings
Eating hints before, during, and after cancer treatment. National Institutes of Health, National Cancer Institute Web site. http://www.cancer.gov/cancertopics/coping/eatinghints/page4#diarrhea. Accessed June 5, 2013.
Mayo Clinic staff. Diarrhea. Mayo Clinic Web site. http://www.mayoclinic.com/health/diarrhea/DS00292. Accessed June 5, 2013.
US National Library of Medicine, National Institutes of Health. Diarrhea. MedlinePlus Web site. http://www.nlm.nih.gov/medlineplus/ency/article/003126.htm. Updated January 26, 2012. Accessed June 5, 2013.

Seeking C Difficile Patients in the UK for a Pilot Testing Process Interview

WorldII

 

PharmaQuest is a medical translation company that organizes the translation and linguistic validation of patient questionnaires. We also review English questionnaires to make them suitable for use in other countries.

We are currently reviewing a short patient questionnaire for use in the UK (from its original US English). This questionnaire is designed for individuals who have had Clostridium difficile associated diarrhea. We are looking for participants who would be willing to participate in our pilot testing process by taking part in a short interview.

The pilot testing (linguistic validation) is done to check the suitability of our text for use in the UK by interviewing five native speakers of UK English who have had CDAD during the past 1 year.Our aim is to assess whether the text is well phrased and suitable for use in the UK. We will ask respondents whether the text is clear for them and what they understand it to mean.

The interviews will take place during April 2014 at a location and time to suit each respondent (we are based in Oxfordshire but can travel).

Respondents will receive £50 for their time (approx. 30-45 minutes). Anyone who would like to take part or who would like any further information can contact

Fiona Miller on 01295 669088 or fiona.miller@pharmaquest-ltd.com

Seeking Patients Who Have Had Three or More Recurrences With a C. difficile Infection

EmoryClinicPhoto

 

 

3 April 2014

Dr. Tanvi Dhere, MD and Dr. Colleen Kraft, MD at Emory University are currently working with a company testing a set of encapsulated fecal transplants (to swallow) for treatment of recurrent C. difficile infection.

The first phase (15 patients) has been completed and patients showed a good response. The delivery is ideal for many patients with C. difficile infection who are elderly and with multiple comorbidities who may have difficulty with colonoscopy.

We are looking for patients who are on their third or more recurrence of C. difficile infection.

Patients with inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) are ineligible.

If you have any potential patients, please have them contact Dr. Colleen Kraft at 404-712-8889 (USA) or email: colleen.kraft@emory.edu.

*Patients please contact Dr. Colleen Kraft directly via: email for additional information and consideration. Also, participants must be willing to travel to Atlanta for 4 study visits

Thank you.

Photo courtesy of E. Ford

 

The C Diff Foundation Welcomes Karen Factor, R.D. Chairperson of Dietary Nutrition

welcome1

 

 

 

We would like to take this opportunity to welcome Karen Factor, R.D., MBA to the

C Diff Foundation; Chairperson of Dietary Nutrition.

Karen Factor, a Registered Dietitian with the Duke Medical System, received her MBA in Dietetics in at the University of New Haven and completed her internship in Dietetics at

St. Raphael’s Hospital in New Haven, CT.

Karen has 25 years of experience in Food-service, Hospitals, Long-term care Facilities, Dialysis Centers, Public Health,a Provider for Blue Cross/Blue Shield and Consultant for Nutritional Weight Loss in NC. She is a Certified Reviewer of Weight Loss Programs in North Carolina, a Breastfeeding Educator under Forsyth Memorial Hospital, and an RD Food Allergy Specialist under the PAC Registered Dietitian Consultant Training Program.

Karen’s background includes experience in caring for patients diagnosed with GERD, C, diff , Crohn’s Disease, and Irritable Bowel Syndrome (IBS).

Publications include: Nutrition Articles for the East Carolina Public Health Association Newsletter, Abstracts and Manuscripts on Renal Nutrition for the University of Missouri Dialysis Conferences and the Renal Nutrition Forum Periodical.